



# Generation of Recombinant Tool Antibodies to Support Cell and Gene Therapy Development

Paola Genevini, PhD  
Technical Sales Specialist  
Bio-Rad Laboratories, Inc.

November 17, 2023

## Background

- Cell and Gene Therapies (CGT) must comply to strict analytical testing requirements to meet regulatory agencies' standards.
- Development of bioanalytical tools is a critical step for the success of CGT.
- Critical reagents used in such assays include antibodies.

## Solution

- Antibody phage display combined with SpyTag technology can generate highly-specific antibodies in a variety of formats for immediate use in relevant applications

## **How to deliver high-quality, critical reagents?**



- Phage display technology applied to CAR T
- SpyTag technology: format switch
- Stable and reliable antibody supply

## **Real case application:**

- Development of antibodies for use in flow QC of CAR T-products

# Antibody Phage Display


- HuCAL PLATINUM®
- Fully synthetic, fully human, Fab library
- High diversity: theoretical library size of 45 billion antibodies
- Fast: library screening in as little as 8 weeks
- Nonanimal-derived antibodies, reducing the use of animals in science



# Guided Selection: Epitope Specificity


**Requirements:** Fab antibodies recognize antigen but not a closely related antigen (CRA)

**Strategy:** Selection on antigen and library subtraction using CRA




# Guided Selection: Epitope Specificity

## CAR-T receptor structure




Target antigen: recombinant scFv portion  
CRA: control scFv






# Antibody Generation Process






# Antibody Generation Process










# Modular Antibodies: One Antibody, Multiple Formats in an Instant



Hentrich C et al. (2021). Periplasmic expression of SpyTagged antibody fragments enables rapid modular antibody assembly. *Cell Chem Biol* 28, 1–12.

# Recombinant Production is Highly Reproducible Between Lots



## Generation of antibodies targeting a chimeric antigen receptor (CAR)


- Antigens: single chain fragment variable (scFv) and biotinylated scFv
- Screenings:
  - Primary: ELISA on scFv, biotinylated scFv, and unrelated scFv, identified **196 hits**
  - Secondary : flow cytometry on scFv expressing cells, resulted in **75 hits**
  - Tertiary : off-rate ( $k_{off}$ ) ranking of positive hits using biolayer interferometry
- Sequencing of the 20 best clones identified **11 unique antibodies**
- Antibodies expressed and purified: 3 different formats provided thanks to TrailBlazer™ technology
- Quality control (QC) by ELISA and flow cytometry

# Off-Rate Ranking Results of Unique Clones


$k_{off}$  ranking data for unique clones.

Measurement on the monovalent Fab

Sensor Location	Antibody Clone	Antigen	Response, nm	$k_{off}$ , 1/s
C8	AbD99991ad-1	scFv-bio	0.59	$5.35 \times 10^{-4}$
C9	AbD99992ad-1	scFv-bio	0.79	$5.11 \times 10^{-4}$
G1	AbD99993ad-1	scFv-bio	0.14	$3.19 \times 10^{-3}$
H1	AbD99994ad-1	scFv-bio	0.16	$4.07 \times 10^{-3}$
E1	AbD99995ad-1	scFv-bio	0.25	$5.86 \times 10^{-3}$
B2	AbD99996ad-1	scFv-bio	0.17	$3.58 \times 10^{-3}$
A2	AbD99997ad-1	scFv-bio	0.14	$3.72 \times 10^{-3}$
C1	AbD99998ad-1	scFv-bio	0.11	$3.63 \times 10^{-3}$
F1	AbD99999ad-1	scFv-bio	0.13	$4.68 \times 10^{-3}$
D1	AbD99990ad-1	scFv-bio	0.26	$2.47 \times 10^{-3}$




# One Antibody Production Leads to Three Formats




# Quality Control ELISA


## Fab



## hIgG-like








## Bivalent Fab-PE



- ELISA with the monovalent Fab format can be used to rank the antibodies according to their binding strength
- Bivalent formats (Fab or Ig-like) can be used in applications that benefit from the avidity effect to offer increased sensitivity



# Flow Cytometry with Anti-scFv Antibody in Ig-Like Format



- NK Natural killer (NK) cell line
- NK- NK cell line transfected with unrelated scFv
- NK+ NK cell line transfected with target scFv
- CART- CAR T-cells transfected with unrelated scFv
- CART+ CAR T-cells transfected with target scFv

# Summary

- Fast, well-established platform for the generation of customized antibodies
- In vitro strategies for meeting challenging specificity requirements
- Screening and testing in relevant applications
- Modular antibody platform with SpyTag incorporated
- Reliable production, lot-to-lot consistency



Visit [bio-rad-antibodies.com/TrailBlazer](https://bio-rad-antibodies.com/TrailBlazer) for more information.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. TRAILBLAZER is a trademark of Bio-Rad Europe (GmbH) in certain jurisdictions. HUCAL and HUCAL PLATINUM are trademarks of MorphoSys AG in certain jurisdictions. All trademarks used herein are the property of their respective owner.

Products containing SpyTag1, SpyTag3, SpyCatcher1, or SpyCatcher3 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, and 10,527,609. Products containing SpyTag2 or SpyCatcher2 and/or their use are covered by the following U.S. patents and/or pending U.S. patent application or their foreign counterparts owned by or under license to Bio-Rad Laboratories, Inc., including, but not limited to, U.S. Patent Nos. 9,547,003, 10,247,727, 10,527,609, and 11,059,867. SpyDisplay technology is covered by U.S. Patent No. 11,453,883 and pending ex-U.S. counterparts.

© 2023 Bio-Rad Laboratories, Inc.